Anti-Human FOLR1 (folate receptor 1) (Mirvetuximab)
Anti-Human FOLR1 (folate receptor 1) (Mirvetuximab)
Product No.: F530
- -
- -
Product No.F530 Clone M9346A Target FOLR1 (folate receptor 1) Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names Folate receptor alpha (FRα); Adult folate-binding protein (FBP); Folate receptor 1; Folate receptor, adult; KB cells FBP; MOv18 Isotype Human IgG1κ |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Hamster Expression Host CHO Cells FC Effector Activity Active Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region
sequence as the therapeutic antibody Mirvetuximab. Mirvetuximab (M9346A) is a
monoclonal antibody that specifically targets Folate receptor 1 (FOLR1). Background Folate receptor 1 (FOLR1), also known as folate receptor alpha (FRα), is a
glycosylphosphatidylinositol-anchored glycoprotein essential for transporting folate into cells.
Elevated FOLR1 levels are linked to poor prognosis in cancers such as breast cancer and
endometrial carcinoma, making it a potential target for cancer therapy. It has also been
investigated as a biomarker for cancer diagnosis and a target for delivering cytotoxic agents,
particularly in cancers affecting women1,2. Mirvetuximab (M9346A) is an antibody-drug conjugate that targets folate receptor alpha (FRα), commonly overexpressed in cancers such as ovarian cancer. The initial phase III FORWARD I trial did not show significant benefits in FRα-positive tumors. However, subsequent studies focusing on patients with high FRα expression produced promising results. Consequently, the US FDA granted accelerated approval for Mirvetuximab in patients with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Mirvetuximab has demonstrated efficacy in reducing the risk of tumor progression or death compared to chemotherapy, providing a valuable treatment option for advanced or recurrent ovarian cancer3. This research-grade biosimilar does not contain the drug conjugate. Antigen Distribution While normally expressed on the apical surfaces of healthy epithelial
tissues, FOLR1 is overexpressed in various solid tumors, including ovarian, breast, lung, and
gastric cancers. Ligand/Receptor Folate and reduced folate derivates NCBI Gene Bank ID UniProt.org Research Area Cancer . Immuno-Oncology . Tumor Suppressors References & Citations1. Liu Y, Lian T, Yao Y. Biomarkers. 2020;25(5):367-374. 2. Ginter PS, McIntire PJ, Cui X, et al. Clin Breast Cancer. 2017;17(7):544-549. 3. G B, Rl C, I V, et al. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2024;34(4). 4. Mirvetuximab - Search Results - MyBioSource. Accessed October 5, 2024. https://www.mybiosource.com/search/mirvetuximab |
Formats Available
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.